| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 05/17/2005 | US6894058 Administering statin drug |
| 05/17/2005 | US6894047 Triazine compounds useful as sorbitol dehydrogenase inhibitors |
| 05/17/2005 | US6894046 For treating eosinophil-dependent inflammatory diseases, asthma |
| 05/17/2005 | US6894042 Azabicyclic compounds for the treatment of disease |
| 05/17/2005 | US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes |
| 05/17/2005 | US6894036 4-dedimethylaminotetracycline derivatives |
| 05/17/2005 | US6894021 Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| 05/17/2005 | US6893627 Method for treating type 2 diabetes with an extract of Artemisia |
| 05/17/2005 | CA2252907C Novel 2,3 disubstituted-4(3h)-quinazolinones |
| 05/17/2005 | CA2234409C Transferrin receptor protein of moraxella |
| 05/17/2005 | CA2147502C Novel 7-(5-substituted cyclopentyl) and (5-substituted cyclopentenyl) heptyl alcohols, heptylamines and heptanoic acid amides, and method of lowering intraocular pressure in the eye of a mammal by administration of these novel compounds |
| 05/12/2005 | WO2005042727A2 Methods of organ regeneration |
| 05/12/2005 | WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| 05/12/2005 | WO2001079525A3 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same |
| 05/12/2005 | US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/12/2005 | US20050101635 Delivering to an external portion of the body passageway of a patient in need of a therapeutically effective amount of an antihistamine or decongestant to treat inflammatory diseases |
| 05/12/2005 | US20050101632 Treating inflammation of the skin or mucous membrane by topical administration of an anti-inflammatory amount of dimethicone in the absence of any other anti-inflammatory agent |
| 05/12/2005 | US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases |
| 05/12/2005 | US20050101567 Using a sulfonamide containing compound |
| 05/12/2005 | US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders |
| 05/12/2005 | US20050101536 Modulation of angiogenesis |
| 05/12/2005 | US20050101534 Side effect reduction of antibiotics; using 2- mercaptan pyrimidine compound |
| 05/12/2005 | US20050101018 Viral vector encoding pigment epithelium-derived factor |
| 05/12/2005 | US20050101014 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury |
| 05/12/2005 | US20050100617 Method for improving age-related physiological deficits and increasing longevity |
| 05/12/2005 | CA2544310A1 New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof |
| 05/12/2005 | CA2543745A1 Methods of organ regeneration |
| 05/11/2005 | EP1529105A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 05/11/2005 | EP1529062A2 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 05/11/2005 | EP1529046A1 Substituted benzimidazole compounds |
| 05/11/2005 | EP1529038A1 Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity |
| 05/11/2005 | EP1529031A1 Acylated arylcycloalkylamines and their use as pharmaceuticals |
| 05/11/2005 | EP1528927A1 Use of carboxamides for the treatment of tinnitus |
| 05/11/2005 | EP1399127B1 Olopatadine formulations for topical administration |
| 05/11/2005 | EP1397363B1 5-ethyl-imidazotriazinones |
| 05/11/2005 | EP1309563B1 Heterocyclic-hydroxyimino-fluorenes and their use for inhibiting protein kinases |
| 05/11/2005 | EP1257526B1 Aniline-derived ligands for the thyroid receptor |
| 05/11/2005 | EP1254138B1 Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase |
| 05/11/2005 | EP1088069B1 Angiostatin-binding protein |
| 05/11/2005 | EP0986408B1 New medicaments based on polymers composed of methacrylamide-modified gelatin |
| 05/11/2005 | CN1615307A Process and intermediates for pyridazinone antidiabetic agents |
| 05/11/2005 | CN1615134A Pharmaceutical compositions comprising valsartan and NEP inhibitors |
| 05/11/2005 | CN1613485A Iron-sheet dendrobe compound drop pellets and their preparation |
| 05/11/2005 | CN1200951C Process for productio nof multiple cross-linked hyaluronic acid derivatives |
| 05/11/2005 | CN1200932C Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect |
| 05/11/2005 | CN1200714C Use of diterpenoid triepoxides as anti-proliferative agent |
| 05/11/2005 | CN1200698C Use of corneal hardening agent in enzyme orthokeratology |
| 05/10/2005 | US6891063 Salts with pharmaceutically acceptable organic bases, selected from ethylenediamine, ethanolamine, diethanolamine, lysine, benzyltrimethylammonium hydroxide and tetramethylammonium hydroxide; antiinflammatory agents, wound healing agents |
| 05/10/2005 | US6890952 Administering cyclic substituted aminomethyl compounds for the preparation of a drug for the treatment of pain, urinary incotinence, itching, tinnitus aurium or diarrhea in a mammal |
| 05/10/2005 | US6890937 Inhibiting the activity of one or more of MMP-2, MMP-9 and MMP-13, while exhibiting substantially less inhibitory activity against MMP-1 |
| 05/10/2005 | US6890928 Aromatic sulfone hydroxamic acids and their use as protease inhibitors |
| 05/10/2005 | US6890927 Tartrate salts of 5,8, 14-triazateracyclo[10.3.1.02,11 04.9]-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| 05/10/2005 | US6890920 Therapeutic treatment of asthma, chronic obstructive pulmonary disease, rhinorrhea due to the common cold, rhinitis |
| 05/10/2005 | US6890915 Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE) |
| 05/10/2005 | CA2303801C Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists |
| 05/10/2005 | CA2183367C Ready-to-use indomethacin collyre |
| 05/06/2005 | WO2005040148A1 New rar$g(b) receptor-activating ligand, method for the preparation thereof and use thereof in human medicine and in cosmetics |
| 05/06/2005 | WO2005039602A1 Pharmacologically functional water and use thereof |
| 05/06/2005 | WO2005039574A1 Therapeutic agent for keratoconjunctive disorder |
| 05/06/2005 | WO2005009436A8 Dispersible formulation of an anti-inflammatory agent |
| 05/06/2005 | WO2004091438B1 Improved ophthalmic and contact lens solutions containing peptides as representative enhancers |
| 05/06/2005 | WO2003010286A3 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 05/06/2005 | WO2002095007A3 Conjugates activated by cell surface proteases and therapeutic uses thereof |
| 05/06/2005 | CA2543555A1 Therapeutic agent for keratoconjunctival disorder |
| 05/06/2005 | CA2543404A1 Novel inhibitor of the formation of advanced glycation end product and aldose reductase inhibitor |
| 05/06/2005 | CA2541123A1 Compositions and methods comprising prostaglandin-related compounds and trefoil factor family peptides for the treatment of glaucoma with reduced hyperemia |
| 05/06/2005 | CA2539193A1 New rarbeta receptor-activating ligand, method for the preparation ther eof and use thereof in human medicine and in cosmetics |
| 05/05/2005 | US20050096468 Inhibitors of histone deacetylase |
| 05/05/2005 | US20050096397 Adding trifluoroacetic acid dropwise to a solution of dimethylphenylsilane and (S)-amino-1-(2,5-dimethoxy-phenyl)-1-propanone, the amino group of which is protected, for example, with a methoxycarbonyl group; reduction; deprotecting; salt formation |
| 05/05/2005 | US20050096388 Compositions and methods for treating or preventing diseases of body passageways |
| 05/05/2005 | US20050096356 2-[[6-Methoxy-3-pyridinyl]methyl]amino-N-[3-(trifluoromethyl)phenyl]benzamide hydrochloride salt or its tautomer; treating retinopathy or age-related macula degeneration |
| 05/05/2005 | US20050096316 Quinoline derivatives(2) |
| 05/05/2005 | US20050096313 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic |
| 05/05/2005 | US20050096310 Antagonist of phosphorylation of myosin regulatory light chain, enzyme inhibitors; therapeutic treatment of glaucoma, bronchial asthma, chronic obstructive pulmonary disease, nervous system disorders; 4-(2,3-dihydro-1,5-diazaphenalen-1-yl)cyclohexylamine |
| 05/04/2005 | EP1528058A1 Polymorphic crystalline forms of celecoxib |
| 05/04/2005 | EP1527781A1 Antipruritic agent |
| 05/04/2005 | EP1527100A2 Human monoclonal antibodies to interleukin-5 and methods and compositions comprising same |
| 05/04/2005 | EP1527070A1 Azole methylidene cyanide derivatives and their use as protein kinase modulators |
| 05/04/2005 | EP1527068A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 05/04/2005 | EP1527063A1 The 9, 11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
| 05/04/2005 | EP1527051A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 05/04/2005 | EP1527046A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 05/04/2005 | EP1526895A2 Methods for treating carbonic anhydrase mediated disorders |
| 05/04/2005 | EP1526869A1 Compositions of a cyclooxygenase-2 selective inhibitor and a carbonic anhydrase inhibitor for the treatment of neoplasia |
| 05/04/2005 | EP1526859A1 Process for preparing a sterile high molecular weight hyaluronic acid formulation |
| 05/04/2005 | EP1526858A2 Use of gaba-c receptor antagonists for the treatment of myopia |
| 05/04/2005 | EP1526853A1 Use of a papaverine-like vasodilator and pharmaceutical composition |
| 05/04/2005 | EP1526851A2 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy |
| 05/04/2005 | EP1526847A2 Pharmaceutical dosage form comprising a sulfite compound |
| 05/04/2005 | EP1526846A2 Gelatin capsule exhibiting reduced cross-linking |
| 05/04/2005 | EP1526845A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 05/04/2005 | EP1526844A2 Pellicle-resistant gelatin capsule |
| 05/04/2005 | EP1395582B1 Novel piperidinecarboxamide derivatives, method for preparing same and pharmaceutical compositions containing same |
| 05/04/2005 | EP1341539B1 Anti-inflammatory agents |
| 05/04/2005 | EP1259477B1 Aminoadamantane derivatives as therapeutic agents |
| 05/04/2005 | EP1246790B1 Substituted 1 and 2 naphthol mannich bases |
| 05/04/2005 | EP1119567B1 Quinazoline derivatives |
| 05/04/2005 | CN1612893A VEGF peptides and their use for inhibiting angiogenesis |
| 05/04/2005 | CN1612869A Novel 1, 2, 4-thiadiazolium derivatives as melanocortin receptor modulators |
| 05/04/2005 | CN1612864A Novel alkansulfonamides as endothelin antagonists |